2023
JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
Shahriari N, Strober B, Shahriari M. JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients. JAAD Case Reports 2023, 33: 81-83. PMID: 36873051, PMCID: PMC9982443, DOI: 10.1016/j.jdcr.2023.01.020.Peer-Reviewed Original Research
2022
33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
Strober B, Chao J, Chuang C, Yang M, Shumel B, Wang J, Bego-Le-Bagousse G, Sierka D, Wang Z, Delevry D. 33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study. Journal Of The American Academy Of Dermatology 2022, 87: ab159. DOI: 10.1016/j.jaad.2022.06.669.Peer-Reviewed Original Research33325 Long-term dupilumab effectiveness on health-related quality of life (HRQoL) and work productivity in atopic dermatitis (AD): Results from RELIEVE-AD
Delevry D, Chao J, Chuang C, Yang M, Shumel B, Martins B, Bego-Le-Bagousse G, Sierka D, Wang Z, Strober B. 33325 Long-term dupilumab effectiveness on health-related quality of life (HRQoL) and work productivity in atopic dermatitis (AD): Results from RELIEVE-AD. Journal Of The American Academy Of Dermatology 2022, 87: ab179. DOI: 10.1016/j.jaad.2022.06.749.Peer-Reviewed Original Research310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis
Gooderham M, Strober B, Ardern-Jones M, Guttman-Yassky E, Levenberg M, Chan G, Biswas P, Watkins M. 310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis. Journal Of Investigative Dermatology 2022, 142: s53. DOI: 10.1016/j.jid.2022.05.318.Peer-Reviewed Original Research
2021
25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5
Kwatra S, Forman S, Cruz A, Ball S, DeLozier A, Pierce E, Buchanan A, Sun L, Ding Y, Strober B. 25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5. Journal Of The American Academy Of Dermatology 2021, 85: ab59. DOI: 10.1016/j.jaad.2021.06.260.Peer-Reviewed Original Research
2013
Treatment of atopic dermatitis in pregnancy
Babalola O, Strober B. Treatment of atopic dermatitis in pregnancy. Dermatologic Therapy 2013, 26: 293-301. PMID: 23914886, DOI: 10.1111/dth.12074.Peer-Reviewed Original Research
2006
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis
Belsito D, Wilson D, Warshaw E, Fowler J, Ehrlich A, Anderson B, Strober B, Willetts J, Rutledge E. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. Journal Of The American Academy Of Dermatology 2006, 55: 40-46. PMID: 16781290, DOI: 10.1016/j.jaad.2006.03.025.Peer-Reviewed Original ResearchConceptsAllergic contact dermatitisNickel-induced allergic contact dermatitisTacrolimus ointmentAdverse eventsContact dermatitisSymptoms of ACDGlobal assessmentChronic allergic contact dermatitisPhysician global assessmentTacrolimus ointment 0.1Pruritus scoreClinical trialsPruritus reductionDay 8TacrolimusDermatitisInner aspectPatientsOintmentSignsTolerabilityArmSymptomsAgentsTrials